532296 Stock Overview
Develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
No risks detected for 532296 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Glenmark Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,436.30 |
| 52 Week High | ₹1,830.05 |
| 52 Week Low | ₹766.65 |
| Beta | 0.93 |
| 1 Month Change | -12.21% |
| 3 Month Change | -15.52% |
| 1 Year Change | 62.07% |
| 3 Year Change | 192.53% |
| 5 Year Change | 340.25% |
| Change since IPO | 5,353.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532296 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.7% | -1.3% | 0.9% |
| 1Y | 62.1% | 20.2% | 6.9% |
Return vs Industry: 532296 exceeded the Indian Pharmaceuticals industry which returned 20.2% over the past year.
Return vs Market: 532296 exceeded the Indian Market which returned 6.9% over the past year.
Price Volatility
| 532296 volatility | |
|---|---|
| 532296 Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: 532296 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532296's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 14,989 | Glenn Saldanha | www.glenmarkpharma.com |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty products, and OTC pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, cardiology, diabetic, gynecology, gastroenterology, and anti-infective in the dosage forms of complex injectables and biologics, oral solids, liquids, topical products, drops, and respiratory/MDI/DPI/nasal sprays. Its product pipeline includes ISB 2001, a BCMA x CD38 x CD3 trispecific engagement by antibodies based on the T cell receptor trispecific antibody, which is in Phase 1 clinical trial for indication of relapsed/refractory multiple myeloma; ISB 1442, a CD38 x CD47 bispecific engagement by antibodies based on the T cell receptor biparatopic bispecific antibody that is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma and acute myeloid leukemia; and GRC 65327, a Cbi-b inhibitor, which is in pre-clinical study for the indication of solid tumors.
Glenmark Pharmaceuticals Limited Fundamentals Summary
| 532296 fundamental statistics | |
|---|---|
| Market cap | ₹405.48b |
| Earnings (TTM) | -₹10.18b |
| Revenue (TTM) | ₹130.80b |
3.1x
P/S Ratio-39.8x
P/E RatioIs 532296 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532296 income statement (TTM) | |
|---|---|
| Revenue | ₹130.80b |
| Cost of Revenue | ₹43.73b |
| Gross Profit | ₹87.06b |
| Other Expenses | ₹97.25b |
| Earnings | -₹10.18b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -36.09 |
| Gross Margin | 66.56% |
| Net Profit Margin | -7.79% |
| Debt/Equity Ratio | 18.5% |
How did 532296 perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield-4%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 20:15 |
| End of Day Share Price | 2025/02/01 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Glenmark Pharmaceuticals Limited is covered by 53 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sriraam Rathi | Anand Rathi Shares and Stock Brokers Limited |
| null null | Anand Rathi Shares and Stock Brokers Limited |
| Ganeshram Jayaraman | Avendus Spark |